Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause
Executive Summary
The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.
You may also be interested in...
Beyond Orkambi: Cystic Fibrosis Pipeline Includes Other Genetic, Symptomatic Therapy Approaches
PTC Therapeutics looks to offer drug therapy for nonsense mutation CF patients, while Corbus is developing an anti-inflammatory, antifibrotic drug that it hopes will benefit the entire CF patient population.
Corbus Believes A Different Inflammation-Fighting Approach Will Serve All CF Patients
The start-up asserts that agonizing the CB2 receptor will “resolve” inflammation, a different approach than used by anti-inflammatory drugs, and one that would pertain to the entire cystic fibrosis patient population.
U.K.’s Verona Explores Cystic Fibrosis Role For Novel Bronchodilator
A U.K. patient charity will fund preclinical studies of RPL554 for cystic fibrosis, Verona’s lead compound already in development for another niche respiratory condition, COPD exacerbations.